PURPOSE: To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes. PATIENTS AND METHODS: In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B-like [LB-like]; n = 763) or low (luminal A-like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first site-specific recurrence was evaluated by using cumulative incidence and competing risks regression analysis. RESULTS: Median follow-up was 12.5 years. The 10-year BCFI was higher for patients with LA-like (86%) BC compared with LB-like (76%), HER2 (73%), and TN (71%; P < .001) BC. TN and HER2 cohorts had higher hazard of BCFI event in the first 4 years after diagnosis (pre-trastuzumab). LB-like cohorts had a continuously higher hazard of BCFI event over time compared with LA-like cohorts. Ten-year overall survival was higher for LA-like (89%) compared with LB-like (83%), HER2 (77%), and TN (75%; P < .001) BC. LB-like subtypes had higher rates of bone as first recurrence site than other subtypes (P = .005). Visceral recurrence as first site was lower for the LA-like subgroup, with similar incidence among the other subgroups when treated with chemotherapy (P = .003). CONCLUSION: BC subtypes have different distant recurrence patterns over time. Defining different patterns of BC recurrence can improve BC care through surveillance guidelines and can guide the design of clinical studies.
RCT Entities:
PURPOSE: To retrospectively evaluate the pattern of recurrence and outcome of node-negative breast cancer (BC) according to major subtypes. PATIENTS AND METHODS: In all, 1,951 patients with node-negative, early-stage BC randomly assigned in International Breast Cancer Study Group Trials VIII and IX with centrally reviewed pathology data were included. BC subtypes were defined as triple negative (TN; n = 310), human epidermal growth factor receptor 2 (HER2) positive (n = 369), and hormone receptor positive with high (luminal B-like [LB-like]; n = 763) or low (luminal A-like [LA-like]; n = 509) proliferative activity by Ki-67 labeling index. BC-free interval (BCFI) events were invasive BC recurrence in local, contralateral breast, nodal, bone, or visceral sites. Time to first site-specific recurrence was evaluated by using cumulative incidence and competing risks regression analysis. RESULTS: Median follow-up was 12.5 years. The 10-year BCFI was higher for patients with LA-like (86%) BC compared with LB-like (76%), HER2 (73%), and TN (71%; P < .001) BC. TN and HER2 cohorts had higher hazard of BCFI event in the first 4 years after diagnosis (pre-trastuzumab). LB-like cohorts had a continuously higher hazard of BCFI event over time compared with LA-like cohorts. Ten-year overall survival was higher for LA-like (89%) compared with LB-like (83%), HER2 (77%), and TN (75%; P < .001) BC. LB-like subtypes had higher rates of bone as first recurrence site than other subtypes (P = .005). Visceral recurrence as first site was lower for the LA-like subgroup, with similar incidence among the other subgroups when treated with chemotherapy (P = .003). CONCLUSION: BC subtypes have different distant recurrence patterns over time. Defining different patterns of BC recurrence can improve BC care through surveillance guidelines and can guide the design of clinical studies.
Authors: Victor R Grann; Andrea B Troxel; Naseem J Zojwalla; Judith S Jacobson; Dawn Hershman; Alfred I Neugut Journal: Cancer Date: 2005-06-01 Impact factor: 6.860
Authors: B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch Journal: Ann Oncol Date: 2006-04-07 Impact factor: 32.976
Authors: Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu Journal: Proc Natl Acad Sci U S A Date: 2003-08-13 Impact factor: 11.205
Authors: Zhiyuan Hu; Cheng Fan; Daniel S Oh; J S Marron; Xiaping He; Bahjat F Qaqish; Chad Livasy; Lisa A Carey; Evangeline Reynolds; Lynn Dressler; Andrew Nobel; Joel Parker; Matthew G Ewend; Lynda R Sawyer; Junyuan Wu; Yudong Liu; Rita Nanda; Maria Tretiakova; Alejandra Ruiz Orrico; Donna Dreher; Juan P Palazzo; Laurent Perreard; Edward Nelson; Mary Mone; Heidi Hansen; Michael Mullins; John F Quackenbush; Matthew J Ellis; Olufunmilayo I Olopade; Philip S Bernard; Charles M Perou Journal: BMC Genomics Date: 2006-04-27 Impact factor: 3.969
Authors: Mervi Jumppanen; Sofia Gruvberger-Saal; Päivikki Kauraniemi; Minna Tanner; Pär-Ola Bendahl; Mikael Lundin; Morten Krogh; Pasi Kataja; Ake Borg; Mårten Fernö; Jorma Isola Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 12.779
Authors: Riley A Hampsch; Jason D Wells; Nicole A Traphagen; Charlotte F McCleery; Jennifer L Fields; Kevin Shee; Lloye M Dillon; Darcy B Pooler; Lionel D Lewis; Eugene Demidenko; Yina H Huang; Jonathan D Marotti; Abigail E Goen; William B Kinlaw; Todd W Miller Journal: Clin Cancer Res Date: 2020-04-22 Impact factor: 12.531
Authors: Kevin Shee; Jason D Wells; Matthew Ung; Riley A Hampsch; Nicole A Traphagen; Wei Yang; Stephanie C Liu; Megan A Zeldenrust; Liewei Wang; Krishna R Kalari; Jia Yu; Judy C Boughey; Eugene Demidenko; Arminja N Kettenbach; Chao Cheng; Matthew P Goetz; Todd W Miller Journal: Clin Cancer Res Date: 2019-09-26 Impact factor: 12.531
Authors: Taiwo Adesoye; Oluwatowo Babayemi; Lauren M Postlewait; Sarah M DeSnyder; Susie X Sun; Wendy A Woodward; Naoto T Ueno; Kelly K Hunt; Anthony Lucci; Mediget Teshome Journal: Ann Surg Oncol Date: 2021-07-22 Impact factor: 5.344
Authors: Jennifer R Bean; Sarah R Hosford; Lynn K Symonds; Philip Owens; Lloye M Dillon; Wei Yang; Kevin Shee; Gary N Schwartz; Jonathan D Marotti; Kristen E Muller; Kari M Rosenkranz; Richard J Barth; Vivian S Chen; Veena R Agarwal; Todd W Miller Journal: Breast Cancer Res Treat Date: 2014-12-10 Impact factor: 4.872
Authors: Richard Ha; Simukayi Mutasa; Jenika Karcich; Nishant Gupta; Eduardo Pascual Van Sant; John Nemer; Mary Sun; Peter Chang; Michael Z Liu; Sachin Jambawalikar Journal: J Digit Imaging Date: 2019-04 Impact factor: 4.056